



ASX ANNOUNCEMENT

4 March 2009

Rights Issue Exceeds Expectations

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** announced today the successful completion of the non-renounceable rights issue, released on 28 January 2009. This resulted in share holder applications for 14.7 million shares, totalling \$1.764 million.

The total capital raised of \$1.764 million is substantially in excess of both the minimum subscription for the Offer and the middle case capital raising scenario of \$1,000,000, which was considered by the Tissue Therapies Board to be the most likely result.

The CEO of Tissue Therapies, Dr Steven Mercer said, "The rights issue has exceeded our expectations by a considerable margin, particularly given the current tough market conditions. The Board is very pleased in this practical demonstration of market confidence in Tissue Therapies and the VitroGro® technology and we are eager to implement our commercialisation timetable."

He went on to say, "Since the release of the rights issue prospectus, patient recruitment for the Canadian clinical trial has continuing to plan with another 2 patients starting treatment last week."

"At the same time, our negotiations with an international potential strategic investor are also progressing well."

The updated Top 20 Shareholder list and Appendix 3B report will be released as soon as the data for these is available.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com